Research
Hormonal
Adiponectin levels are inversely correlated with obesity and insulin resistance, and its deficiency contributes to insulin resistance, while its overexpression improves insulin sensitivity.
Lifestyle interventions that increase adiponectin (such as exercise and weight loss) are beneficial. Since adiponectin is low in obesity, improving metabolic health involves restoring this protective hormone.
GoodSupportsHIGH confidence
Levels of adiponectin are low in obese subjects, and treatment with adiponectin increases insulin sensitivity in animal models... A deficiency of adiponectin in mice induces insulin resistance, whereas over-expression of adiponectin in mice improves insulin sensitivity and glucose tolerance
Why this rating
Consistent findings across multiple animal models and human correlations cited in the review.
Source
Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease
Un Ju Jung et al. · International Journal of Molecular Sciences · 2014
DOI 10.3390/ijms15046184
narrative_reviewCited 1,878×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-induced adipose tissue dysfunction, characterized by hypertrophy and macrophage infiltration, drives systemic insulin resistance and metabolic disease through the dysregulated secretion of pro-inflammatory adipokines (e.g., TNF-α, IL-6, MCP-1) and elevated free fatty acids, rather than fat mass alone.Good
- Saturated fatty acids contribute to insulin resistance by inducing ceramide synthesis, whereas unsaturated fatty acids do not, and inhibiting ceramide synthesis can ameliorate this resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →